APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Amyotrophic Lateral Sclerosis (ALS) Treatment

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

Selected research

Market Structure

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173963220321 December 2025189 pages

Choose your research edition.

Industry ResearchAmyotrophic Lateral Sclerosis (ALS) Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.

Read the full market overview

North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.

In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

Report Includes

This report provides an overview of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Amyotrophic Lateral Sclerosis (ALS) Treatment and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Amyotrophic Lateral Sclerosis (ALS) Treatment revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Amyotrophic Lateral Sclerosis (ALS) Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Company

Mitsubishi Tanabe Pharma

Sanofi

Mylan Pharma

Apotex

Glemark Generics

Covis Pharma

Sun Pharma

Lunan Pharma

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application

Hospital

Drugs Store

Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Amyotrophic Lateral Sclerosis (ALS) Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Amyotrophic Lateral Sclerosis (ALS) Treatment industry.

Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Amyotrophic Lateral Sclerosis (ALS) Treatmentrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Riluzole Table 3. Key Players of Edaravone (Radicava) Table 4. Key Players of Other Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Table 6. Key Players of Drugs Store Table 7. Key Players of Other Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2021-2026) Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2027-2032) Table 13. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends Table 14. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Drivers Table 15. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Opportunities and Challenges Table 16. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Restraints Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Company (2021-2026) Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Company Head Office and Area Served Table 21. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company, Product Type & Application Table 22. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2027-2032) Table 35. Mitsubishi Tanabe Pharma Company Information Table 36. Mitsubishi Tanabe Pharma Business Overview Table 37. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 39. Mitsubishi Tanabe Pharma Recent Development Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 44. Sanofi Recent Development Table 45. Mylan Pharma Company Information Table 46. Mylan Pharma Business Overview Table 47. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 49. Mylan Pharma Recent Development Table 50. Apotex Company Information Table 51. Apotex Business Overview Table 52. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 54. Apotex Recent Development Table 55. Glemark Generics Company Information Table 56. Glemark Generics Business Overview Table 57. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 59. Glemark Generics Recent Development Table 60. Covis Pharma Company Information Table 61. Covis Pharma Business Overview Table 62. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 64. Covis Pharma Recent Development Table 65. Sun Pharma Company Information Table 66. Sun Pharma Business Overview Table 67. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 69. Sun Pharma Recent Development Table 70. Lunan Pharma Company Information Table 71. Lunan Pharma Business Overview Table 72. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 74. Lunan Pharma Recent Development Table 75. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026) & (US$ Million) Table 76. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032) & (US$ Million) Table 77. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026) & (US$ Million) Table 78. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032) & (US$ Million) Table 79. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026) Table 81. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032) Table 82. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026) & (US$ Million) Table 83. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032) & (US$ Million) Table 84. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026) & (US$ Million) Table 85. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032) & (US$ Million) Table 86. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026) Table 88. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032) Table 89. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026) & (US$ Million) Table 90. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032) & (US$ Million) Table 91. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026) & (US$ Million) Table 92. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032) & (US$ Million) Table 93. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026) & (US$ Million) Table 94. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032) & (US$ Million) Table 95. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026) & (US$ Million) Table 96. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032) & (US$ Million) Table 97. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026) Table 99. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032) Table 100. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026) & (US$ Million) Table 101. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032) & (US$ Million) Table 102. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026) & (US$ Million) Table 103. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032) & (US$ Million) Table 104. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026) Table 106. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032) Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Product Image Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type: 2025 VS 2032 Figure 4. Riluzole Image Figure 5. Edaravone (Radicava) Image Figure 6. Other Image Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application: 2025 VS 2032 Figure 9. Hospital Image Figure 10. Drugs Store Image Figure 11. Other Image Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2021-2032) Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 24. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032) Figure 25. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032) Figure 26. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032) Figure 27. United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 28. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 30. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 31. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032) Figure 32. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032) Figure 33. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032) Figure 34. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 35. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 37. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 38. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 40. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 41. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032) Figure 42. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032) Figure 43. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 44. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032) Figure 45. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032) Figure 46. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032) Figure 47. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 51. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 52. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032) Figure 57. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 62. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 64. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Riluzole
  • Edaravone (Radicava)
  • Other
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • Mylan Pharma
  • Apotex
  • Glemark Generics
  • Covis Pharma
  • Sun Pharma
  • Lunan Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Riluzole
  5. 1.2.3 Edaravone (Radicava)
  6. 1.2.4 Other
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Drugs Store
  11. 1.3.4 Other
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Region
  14. 1.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2021-2026)
  16. 1.5.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
  1. 2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
  2. 2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Drivers
  3. 2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Opportunities and Challenges
  4. 2.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Company (2021-2026)
  2. 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Company Head office and Area Served
  4. 3.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company, Product Type & Application
  5. 3.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Amyotrophic Lateral Sclerosis (ALS) Treatment Tier 1, Tier 2, and Tier 3
4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Type
  1. 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2032)
  3. 4.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Type (2021-2032)
5 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
  1. 5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2032)
  3. 5.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Mitsubishi Tanabe Pharma
  2. 6.1.1 Mitsubishi Tanabe Pharma Company Information
  3. 6.1.2 Mitsubishi Tanabe Pharma Business Overview
  4. 6.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  6. 6.1.5 Mitsubishi Tanabe Pharma Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Mylan Pharma
  14. 6.3.1 Mylan Pharma Company Information
  15. 6.3.2 Mylan Pharma Business Overview
  16. 6.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  18. 6.3.5 Mylan Pharma Recent Developments
  19. 6.4 Apotex
  20. 6.4.1 Apotex Company Information
  21. 6.4.2 Apotex Business Overview
  22. 6.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  24. 6.4.5 Apotex Recent Developments
  25. 6.5 Glemark Generics
  26. 6.5.1 Glemark Generics Company Information
  27. 6.5.2 Glemark Generics Business Overview
  28. 6.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  30. 6.5.5 Glemark Generics Recent Developments
  31. 6.6 Covis Pharma
  32. 6.6.1 Covis Pharma Company Information
  33. 6.6.2 Covis Pharma Business Overview
  34. 6.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  36. 6.6.5 Covis Pharma Recent Developments
  37. 6.7 Sun Pharma
  38. 6.7.1 Sun Pharma Company Information
  39. 6.7.2 Sun Pharma Business Overview
  40. 6.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  42. 6.7.5 Sun Pharma Recent Developments
  43. 6.8 Lunan Pharma
  44. 6.8.1 Lunan Pharma Company Information
  45. 6.8.2 Lunan Pharma Business Overview
  46. 6.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  48. 6.8.5 Lunan Pharma Recent Developments
7 North America
  1. 7.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
  2. 7.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
  3. 7.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026)
  4. 7.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032)
  5. 7.2.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032)
  6. 7.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
  7. 7.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026)
  8. 7.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032)
  9. 7.3.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032)
  10. 7.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
  11. 7.4.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
  13. 7.4.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032)
  14. 7.4.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
  2. 8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
  3. 8.2.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026)
  4. 8.2.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032)
  5. 8.2.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032)
  6. 8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
  7. 8.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026)
  8. 8.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032)
  9. 8.3.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032)
  10. 8.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
  11. 8.4.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
  13. 8.4.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032)
  14. 8.4.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
  2. 9.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
  3. 9.2.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026)
  4. 9.2.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032)
  5. 9.2.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032)
  6. 9.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
  7. 9.3.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026)
  8. 9.3.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032)
  9. 9.3.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
  2. 10.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
  3. 10.2.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026)
  4. 10.2.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032)
  5. 10.2.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032)
  6. 10.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
  7. 10.3.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026)
  8. 10.3.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032)
  9. 10.3.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032)
  10. 10.4 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
  11. 10.4.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
  13. 10.4.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032)
  14. 10.4.4 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst